Skip to main content
Equibles

VRXA · Veraxa Biotech AG - Post de-SPAC

Track VRXA — free

Use VRXA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VRXA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.13 +0.00 (+0.00%) At close · Oct 5
Rebalance outlook locked
Market Cap
$199.39M
Shares
141.41M
Volume · Oct 5 154.08K Avg daily vol (3M) 396.74K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.13 Open$1.15 Day$1.11–1.15 52W close$1.13–24.79 Avg vol 30d294K Short int210K · 0.1% float · 1.0d Short vol10% DataSep 2024–Oct 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-89.2%
Trailing year
Short interest
0.1%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.59
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −86%
below
Price vs 50-day avg −31%
below
RSI (14) 27
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −26%
trailing
6-month return −91%
trailing
YTD return −89%
this year
Relative strength −103%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+31 funds added
Insider flow Accumulating
Net +$82.7K over 90 days · 0% sells
Short interest Rising
0.15% of float · ▲ +3.3% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
31 holders — 13F breadth
Squeeze score 37
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 133%
annualized · 1-yr
Max drawdown −95%
past year
ATR 12.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−86% Bearish
Price vs 50-day avg
−31% Bearish
RSI (14)
27 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+31 funds added
Insider flow Accumulating
Net +$82.7K over 90 days · 0% sells
Short interest Rising
0.15% of float · ▲ +3.3% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
31 holders — 13F breadth
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $25
vs 200-day avg -86% vs 50-day avg -31%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VRXA
Veraxa Biotech AG - Post de-SPAC
this stock
$199.39M -89.4% — — 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
31
% held
6.8%
Net QoQ
+9.6M sh
Top holder
CSS LLC/IL
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
209.7K
Days to cover
1.0d
Change
+6.8K sh
View
Short Volume
Short vol %
10%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
10.6K
Value
$17.5K
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
64.9%
Week of
Aug 31, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$82.7K
Buyers / Sellers
2 / 0
Buyers Sellers
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 4, 2026
This year
8
View
Earnings & Events
Webcasts
Last webcast
Sep 30, 2026
View
Investor Relations
Latest news
VERAXA Biotech Appoints Raju Will…
Published
Sep 4, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
VRXA -19.9% -26.1% -90.7% -9.6% -89.4%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -19.6% -25.7% -102.9% -10.5% -102.3%
Key facts CIK 2079109 CUSIP H9130A103 Visit website Investor relations